Jan/Feb 2026 • PharmaTimes Magazine • 36-37
// YOUR MOVES //
Your Moves
Mover of the Month
Ahmed Moussa has been appointed as the new Sanofi Country Lead for the UK & Ireland, taking over from Rippon Ubhi.
In his new role, Ahmed will work as a key partner to Governments and health services to improve access to innovative medicines and vaccines for patients and the public.
He will also be looking to champion the UK life sciences sector and help return it to international competitiveness as an attractive location for inward investment.
Ahmed brings nearly 18 years of tenure at Sanofi, including spearheading global omnichannel transformation and contributing significantly to different commercial roles in the Greater Gulf region across diabetes, cardiovascular, oncology, specialty care and market access.
Ahmed said: "I'm truly honoured to be appointed to this role at a time of so many opportunities in the UK. The UK represents a unique healthcare landscape with distinctive challenges and remarkable potential, and I'm genuinely excited to be Sanofi's new voice here.
He added: “With the support of our talented and dynamic teams, I'm committed to championing innovation and advocating for all patients to have access to the best health solutions available."
Qureight, a techbio company advancing the understanding of lung and heart disease through application of its AI-powered CT imaging biomarkers and clinical data management platform in clinical trials, has announced the appointment of Rebecca Simmons as Chief Operating Officer.
Rebecca will be responsible for scaling the company’s global business operations and leading sustainable growth initiatives, as Qureight drives increased adoption and integration of its AI-powered CT imaging biomarkers and clinical data management platform in clinical trials for lung and heart diseases.
She will play an instrumental role in driving operational excellence and supporting Qureight’s scientific and technical functions.
With over 20 years of operational leadership experience, Rebecca was previously COO at quantum computing company Riverlane, where she successfully built and scaled the company’s operations to support rapid growth from ten to 100 employees over five years.
Muhunthan Thillai MD, co-founder and CEO, Qureight, commented: "Rebecca’s experience, expertise and people-centric leadership approach will be instrumental in supporting the team as we scale the company, accelerating our mission to advance the understanding of lung and heart disease."
Rebecca added: "Qureight’s pioneering AI-powered CT imaging biomarkers and data management platform is enabling real insights to be drawn from complex and diverse health data to ultimately deliver real impact for patients."
Gifthealth has announced the appointment of Jeremy Richardson as its new Chief Commercial Officer (CCO).
Richardson brings nearly two decades of leadership experience in sales, marketing, trade and business development across some of the most respected organisations in healthcare.
Most recently, he served as Vice President of Strategy & Commercial Growth at Elevance Health.
Prior to Elevance Health, he spent a decade at Kroger Specialty Pharmacy, rising through the organisation to become Vice President of Sales, Marketing & Trade Relations.
Under his leadership, Kroger achieved consistent year-over-year revenue growth exceeding $4bn, launched new therapeutic divisions and successfully integrated into Elevance.
"Jeremy is known for his ability to architect and execute large-scale commercial strategies – uniting payer, provider and pharma relationships to drive sustainable growth," said Gifthealth CEO Chip Parkinson. "His deep expertise in specialty and infusion therapies, omnichannel marketing and trade relations will be instrumental as Gifthealth accelerates its partnerships with leading pharmaceutical manufacturers and expands patient access."
In his new role, Richardson will oversee all commercial strategy, new business development and marketing functions.
"Gifthealth is transforming patient access, unifying every step of the journey to deliver effortless experiences for manufacturers, patients and prescribers and accelerating speed to therapy," said Jeremy. "I am excited to lead the next phase of its growth across pharma partnerships, as well as its expanding specialty hub and digital pharmacy footprint."
NanoSyrinx, a synthetic biology company developing nanosyringes as a novel platform for targeted intracellular delivery of biologic therapeutics, has announced the appointment of Thomas J Farrell as Chief Executive Officer and Director.
Tom succeeds company founder Joe Healey, who will remain involved in the company, ensuring continuity and ongoing scientific leadership at NanoSyrinx as it enters a pivotal stage of development to deliver the future of intracellular medicine.
Tom brings over 25 years of biotherapeutics leadership, with extensive experience in building and scaling organisations from early-stage drug discovery through pivotal clinical trials.
He was the founding CEO of two NASDAQ-listed companies, successfully raised over $500 million in financing from private investors, strategic partners and public markets, and has been at the forefront of next-generation therapy development in the settings of oncology, immunology and monogenic diseases.
"Tom’s exceptional track record in progressing therapies from concept to clinic, combined with his global perspective, will be invaluable as NanoSyrinx moves from platform development to establishing a robust clinical pipeline," said Edwin Moses, Chairman of the Board at NanoSyrinx.
NanoSyrinx is entering a pivotal stage as it transitions from platform development to building a differentiated pipeline of first-in-class nanosyringe-enabled biotherapeutics.
Its breakthrough nanosyringe technology enables the precise, direct delivery of protein therapeutics into the cytosol of target cells, overcoming a major challenge in in vivo intracellular drug delivery.
Before joining NanoSyrinx, Tom was President of Oricell Therapeutics, a Shanghai-based clinical-stage CAR-T company, where he was responsible for the launch of US clinical trials and positioning the company to access US capital markets.
He has recently served as interim CEO for several innovative cell and gene therapy ventures.
Blue Cell Therapeutics, a biotech developing 'off-the-shelf' allogeneic stem cell therapies for diseases where angiogenesis and nerve regeneration are beneficial, has announced the appointment of Miguel Forte to its Board of Directors.
Miguel is a highly regarded industry executive with more than two decades of operational and strategic leadership experience.
He currently serves as President and Chair of the Board of Directors at the International Society for Cell & Gene Therapy. His appointment to Blue Cell’s board comes just two months after another leading executive, Olav Hellebø, joined as the company’s chairman.
Søren P Sheikh, Chief Executive Officer of Blue Cell Therapeutics, said: "Miguel’s deep scientific knowledge of cell therapy, combined with his extensive experience leading biotechs, gives him a rare business acumen that will be invaluable to Blue Cell Therapeutics.”
Miguel is currently Chief Executive Officer of Kiji Therapeutics, which is developing off-the-shelf engineered cell therapies for inflammatory and autoimmune conditions. He also holds positions on the boards of Swarm Oncology, StemBond Technologies and Akatsuki Therapeutics.
Previously he served as Chief Executive Officer of Bone Therapeutics, where he led the publicly listed company through multiple capital raises and a successful M&A transaction.
Prior to that he was CEO of Zelluna Immunotherapy, where he established the company’s structure, secured key financing, established its leadership team and launched its strategy to develop allogeneic cell and gene therapies targeting solid tumours.
Enhanced Genomics, the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, has announced that Katerina Leftheris has joined its board of directors.
Katerina’s appointment as a director forms part of the company’s ongoing strategy to expand its internal therapeutics pipeline for drug targets identified using its 3D multi-omics platform.
Most recently, Katerina was Chief Scientific Officer at a machine learning-based oral macrocycle drug development company, Vilya, and is on the board of directors and scientific advisory boards for several biotech companies focused on therapeutics development.
Bringing extensive experience, particularly in medicinal chemistry and drug discovery programmes, Katerina will support the executive team in driving development of Enhanced’s internal therapeutics pipeline for drug targets identified using its 3D multi-omics platform, GenLink.
Dietrich A Stephan, Executive Chair, Enhanced Genomics, said: "I am thrilled to welcome Katerina as the newest member of our board. Her exceptional expertise in therapeutics discovery and clinical drug development will be an invaluable asset as we progress our ambitious plans to drive the next era of precision therapeutics development."
Katerina added: "Building on decades of genomics research, Enhanced’s 3D multi-omics platform has the potential to define causal biology, enabling the identification of high-confidence, first-in-class therapeutic targets to drive the development of truly disease-modifying therapies."
PharmaTimes
PharmaTimes is the UK’s leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative and trustworthy content through impartial, balanced and informed opinion and analysis.